Key Takeaways
- Growth masked by investment drag: Revenue grew ~15% in FY25, but EBITDA margin compressed to 12.7% as the company front-loaded costs for the Institutional & B2C vertical, which scaled 67% to ~₹300 crore.
- A new vertical emerges, with near-term margin pain: The Institutional & B2C business is now disclosed separately, but its scaling investments pushed Buzil EBITDA negative and weighed on consolidated margins, a trade-off management expects to reverse in FY26.
- Ethylene Oxide is the swing factor: HPPC growth was capped by EO supply constraints from Reliance; management is betting on higher availability and a new continuous Ethoxylation plant to unlock low double-digit growth and higher-margin chemistries.
- A ₹192 crore CAPEX bet on backward integration: The board approved new projects in non-EO Esters, Monomers, and Mellitic space, targeting 2x-3x asset turns and commissioning by Q4 FY26.
- What to watch next quarter: Whether the Dahej and Unitop expansions commission on schedule in Q2 FY26, any signal on improved EO allocation from Reliance, and whether the Institutional & B2C vertical starts delivering the promised low single-digit EBITDA.
The Institutional & B2C Bet
- Scale achieved, profitability pending: The vertical grew 67% to ~₹300 crore in FY25 and is now a separately disclosed segment. The core business within it delivers a healthy ~15% adjusted EBITDA, but the overall vertical is still investment-heavy, dragging consolidated margins.
- Buzil margin mechanics: Gross margins are stable at 26%-27%, but EBITDA turned negative because the business is still investing in manpower, selling, distribution, and network setup. The ₹124 crore revenue increase did not cause a proportionate ₹10 crore EBITDA dip; the costs are upfront and expected to peak out.
- The one-stop-shop logic: Management argues that institutional customers like Taj, ITC, and Marriott demand a single supplier across categories. The Freshee brand is already in Reliance Retail and Lulu, using existing manufacturing infrastructure to fill machines rather than building new lines.
- Tissues and foils seeding: The company started seeding the market via trading and toll manufacturing, with a plan to move most production in-house over the current year. A small setup for tissues is already operational.
Chari: "When we go to a customer like a Taj Hotel or ITC Hotel or a Marriott or a Hyatt or a Hilton, we need to be a one-stop shop. Otherwise, they will not entertain us."
Ethylene Oxide: The Constraint and the Workaround
- EO availability capped HPPC growth: Growth in the HPPC division was limited by Ethylene Oxide supply constraints from Reliance. Management worked on non-EO initiatives through last year, with some execution expected to begin in FY26.
- The supply outlook is cautiously optimistic: Based on discussions with Reliance, management expects higher EO availability and is guiding for low double-digit growth (~10%) in the Ethoxylate portion of HPPC. If supply remains tight, EO will be allocated to maximum-margin products, so EBITDA should still improve year-on-year.
- New plant unlocks new chemistries: The continuous Ethoxylation plant expansion, commissioning in Q2 FY26, enables production of Amine, gas shifting agents, and H2S scavengers, derivatives that carry higher margins than standard Ethoxylates.
- Acrylic acid risk recedes: Acrylic acid is now a very small percentage of total input costs, with local availability from BPCL Kochi reducing import dependence. Price increases still hit gross margins but not as significantly as in the past.
CAPEX: Backward Integration and New Chemistries
- ₹192 crore approved: The board sanctioned ₹97 crore for Unitop Chemicals and Tristar Intermediates, and ₹95 crore for Rossari Biotech. These projects target non-EO products (Esters, Monomers) for backward integration, plus new chemistries in the Mellitic space.
- Asset turn expectations: Management expects 2x-3x asset turns on the backward integration CAPEX. The projects will be commissioned in a phased manner by Q4 FY26.
- Previously announced expansions on track: The Dahej and Unitop expansions are progressing per the revised plan, with commissioning expected by Q2 FY26.
- Broader backward integration push: Beyond the approved CAPEX, the company is working to increase backward integration for raw materials including various Esters, Phenols, vegetable oil-related chemicals, and hydrogenation.
- Biosurfactant capacity addition: A big fermenter is being added to increase production of the Sophorolipids platform, an in-house biosurfactant line relevant across more than 10 industries.
Cost Structure: The Investment Phase
- Costs surged on growth initiatives: Employee costs rose 42% YoY and other expenses 59% YoY, driven by higher production and sales, freight, selling expenses, travel, exhibitions, and a headcount increase of ~140-145 people across consumer business, core sales, and R&D.
- R&D scaling underway: New R&D centers were set up at Tristar and Dahej, and senior R&D hires were brought into Mumbai, with a dedicated facility expected later this year.
- Core business discipline intact: Shorn of the BRPL and Pet business, the core business has done well and costs have not risen significantly there. The steep increases are concentrated in future growth initiatives and the consumer business, where expenses are steeper in the growth phase.
- Cost run rate expected to stabilize: Management expects the current quarterly run rate to hold through FY26: employee costs at ₹30-35 crore per quarter and other expenses at ~₹65 crore per quarter, with paybacks from these investments starting to materialize.
Sablok: "So, my take is that the current quarterly run rate, we should be around that for the next year. So, employee cost, my expectation is that we will be at that Rs. 30- Rs. 35 crore run rate. And the other expenses should be around Rs. 65 crore plus-minus per quarter."
Exports and Geopolitical Positioning
- Exports grew 27% in FY25: Presence expanded to over 70 countries, driven by focused efforts on strategic markets, deepening customer relationships, and innovation-led customized solutions.
- Trump tariffs seen as a tailwind: Management views the tariffs as a blessing rather than a curse, since they are directed more at China, Thailand, Malaysia, and Indonesia, potentially opening opportunities for Indian manufacturers.
- Bangladesh strategy recalibrated: Demand from Bangladesh has not dropped significantly, but the company is being selective on customers due to foreign currency issues. It is going slow there and has started exploring other geographies for textile exports, including Southeast Asia, Egypt, and Turkey.
- Global uncertainty clouds the medium term: Management declined to provide a clear 3-year vision, citing geopolitical uncertainties around China/Taiwan, Iran, Ukraine, and tariffs.
Chari: "At the moment, we are not clear on what the future is. The skies are not clear. The path is not clear. We are not able to tell you."
Margin Outlook and Recovery Path
- Core business margin target: Shorn of the consumer business, core EBITDA margins should be in the 14.5%-15% range. The overall company EBITDA margin target is 13%-13.5%.
- Buzil breakeven expected in FY26: Management hopes the Institutional and Consumer business will show some positive EBITDA on an annualized basis in FY26, targeting a low single-digit EBITDA number.
- Working capital improving: Inventory levels increased in line with strategy to build stocks ahead of the Agro season and planned supplier shutdowns. Receivables are down 2 days, and further improvements are targeted through FY26.
- FY27 as the inflection year: Management indicated FY27 should be a much better year, with CAPEX on stream, EO availability issues hopefully resolved, and additional EO capacities coming through. However, no specific growth or margin numbers were committed.
Sablok: "It's not proper to read it in a manner that Rs. 124 crore of additional sales have brought in Rs. 10 crore of dip in the EBITDA."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Dahej and Unitop expansions | Commissioning as per revised plan | Q2 FY26 |
| New CAPEX (₹192 crore) | Phased commissioning of backward integration and new chemistry projects | By Q4 FY26 |
| Continuous Ethoxylation plant | Start of operations, enabling new higher-margin chemistries | Q2 FY26 |
| HPPC Ethoxylate growth | Low double-digit growth (~10%), contingent on higher EO availability from Reliance | FY26 |
| Overall revenue growth | At least mid-teens level | FY26 |
| Core business EBITDA margin | 14.5%-15% range (shorn of consumer business) | FY26 |
| Overall company EBITDA margin | 13%-13.5% target | FY26 |
| Institutional & Consumer (Buzil) EBITDA | Low single-digit positive EBITDA on an annualized basis | FY26 |
| Employee cost run rate | ₹30-35 crore per quarter | FY26 |
| Other expenses run rate | ~₹65 crore per quarter | FY26 |
| New CAPEX asset turns | 2x-3x on backward integration projects | Post-commissioning |
| Tissues and foils production | Move most into in-house production facility | Over the current year (FY26) |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue from operations | ₹579.6 crore, up 22.6% YoY |
| EBITDA | ₹69.5 crore, up 9.3% YoY |
| EBITDA margin | 12%, compared to 13.5% in Q4 FY24 |
| Full-year FY25 revenue from operations | ₹2,080 crore, up 13.6% YoY |
| Full-year FY25 EBITDA | ₹265.1 crore, up 6.1% YoY |
| Full-year FY25 EBITDA margin | 12.7%, compared to 13.6% in FY24 |
| Institutional and B2C business FY25 revenue | ₹299 crore, up 67% YoY |
| Adjusted EBITDA margin, core business (ex-Institutional and B2C) FY25 | ~15% |
| Exports growth FY25 | 27%, presence expanded to over 70 countries |
| Q4 FY25 exports | ₹162 crore, compared to ₹127 crore in Q4 FY24 |
| Total CAPEX approved | ~₹192 crore, covering expansions at subsidiaries and Rossari Biotech, phased commissioning by Q4 FY26 |
| Net debt, FY25 end | ₹70 crore |
| Average cost of debt | 8% |
| Dividend recommended per share FY25 | ₹0.50 |
| Capacity utilization, Ethoxylation | Completely utilized at Unitop and Tristar |
| Capacity utilization, formulation side | 50%–55% |
| Employee cost expected quarterly run rate | ₹30–35 crore |
| Other expenses expected quarterly run rate | ₹65 crore plus-minus |
| Headcount increase | 140–145 people between the two years |
| Overall company EBITDA margin target | 13%–13.5% |
| Core business EBITDA margin target | 14.5%–15% |
| Annualized top line growth target | ~15% |
| Buzil gross margins | 26%–27% range for FY25 and FY24 |
| Working capital improvement | 2 days compared to last year |
| Receivables reduction | 2 days |